DK1670315T3 - Fremgangsmåder til anvendelse af fedtafledte regenerative celler i behandlingen af perifer karsygdom - Google Patents
Fremgangsmåder til anvendelse af fedtafledte regenerative celler i behandlingen af perifer karsygdom Download PDFInfo
- Publication number
- DK1670315T3 DK1670315T3 DK04756641.9T DK04756641T DK1670315T3 DK 1670315 T3 DK1670315 T3 DK 1670315T3 DK 04756641 T DK04756641 T DK 04756641T DK 1670315 T3 DK1670315 T3 DK 1670315T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- tissue
- composition
- regenerative
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Claims (34)
- FREMGANGSMÅDER TIL ANVENDELSE AF FEDTAFLEDTE REGENERATIVE CELLER I BEHANDLINGEN AF PERIFER KARSYGDOM1. Sammensætning omfattende en koncentreret population af fedtvævsafledte celler til anvendelse i behandlingen af perifer karsygdom (PVD) uden for hjertet og centralnervesystemet hos et subjekt med behov derfor, hvori den koncentrerede population af fedtafledte celler skal administreres til en patient med behov derfor uden at dyrke de fedtafledte celler, før de administreres til subjektet, hvori de fedtafledte celler opnås ved at behandle fedtvæv, så de fedtafledte celler separeres fra modne adipocytter og bindevæv, og vaske, separere og koncentrere de fedtafledte celler, hvori den koncentrerede population af fedtvævsafledte celler omfatter en minimumscellekoncentration på omkring 1 x 105 til omkring 1 x 107 celler/ml, og hvori mindst 0,1 % af cellekomponenten af den koncentrerede population af fedtafledte celler er stamceller.
- 2. Sammensætning til anvendelse ifølge krav 1, hvori den koncentrerede population af fedtvævsafledte celler endvidere omfatter fedtafledte progenitor-celler.
- 3. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvori sammensætningen endvidere omfatter et additiv.
- 4. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvori sammensætningen omfatter et scaffold.
- 5. Sammensætning til anvendelse ifølge krav 4, hvori scaffoldet er et resorberbart scaffold.
- 6. Sammensætning til anvendelse ifølge krav 4, hvori cellerne administreres i kombination med væv eller vævsfragmenter, og hvori ekstraktion og koncentration af fedtvævet og placering af cellerne sker i en enkelt operativ procedures kontekst.
- 7. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvori de fedtvævsafledte celler er modificeret ved genoverførsel.
- 8. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvori den perifere karsygdom er karakteriseret ved en aberrant blodgennemstrømning, arteriosklerose en traumatisk skade på et blodkar eller en inflammatorisk arteritis.
- 9. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvori den perifere karsygdom stammer fra kulde, stress eller rygning.
- 10. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvori sammensætningen endvidere omfatter en angiogen faktor eller et immunsupprimerende lægemiddel.
- 11. Sammensætning ifølge et hvilket som helst af de foregående krav, hvori sammensætningen er formuleret til intravenøs, intramuskulær eller subkutan administration.
- 12. Sammensætning ifølge et hvilket som helst af de foregående krav, hvori behandlingen af perifer karsygdom (PVD) uden for hjertet og centralnervesystemet omfatter reduktion i claudicatio.
- 13. Sammensætning ifølge et hvilket som helst af de foregående krav, hvori behandlingen af perifer karsygdom (PVD) uden for hjertet og centralnervesystemet omfatter heling af iskæmiske ulcerationer.
- 14. Sammensætning ifølge et hvilket som helst af de foregående krav, hvori behandlingen af perifer karsygdom (PVD) uden for hjertet og centralnervesystemet omfatter øgning af oxygenkoncentrationen i vævet målt ved kropspletysmografi.
- 15. Sammensætning ifølge et hvilket som helst af de foregående krav, hvori behandlingen af perifer karsygdom (PVD) uden for hjertet og centralnervesystemet omfatter forbedring i det ankel-brakiale indeks (ABI).
- 16. Sammensætning ifølge et hvilket som helst af de foregående krav, hvori sammensætningen er formuleret til flerdosisadministration.
- 17. Sammensætning til anvendelse ifølge krav 3, hvori additivet omfatter andre celler, væv eller vævsfragmenter.
- 18. Anvendelse af en sammensætning omfattende en koncentreret population af fedtvævsafledte celler til fremstilling af et medikament til behandling af perifer karsygdom (PVD) uden for hjertet og centralnervesystemet hos et subjekt med behov derfor, hvori den koncentrerede population af fedtafledte celler skal administreres til en patient med behov derfor uden at dyrke de fedtafledte celler, før de administreres til subjektet, hvori de fedtafledte celler opnås ved at behandle fedtvæv, så de fedtafledte celler separeres fra modne adipocytter og bindevæv, og vaske, separere og koncentrere de fedtafledte celler, hvori den koncentrerede population af fedtvævsafledte celler omfatter en minimumscellekoncentration på omkring 1 x 105 til omkring 1 x 107 celler/ml, og hvori mindst 0.1 % af cellekomponenten af den koncentrerede population af fedtafledte celler er stamceller.
- 19. Anvendelse af en sammensætning ifølge krav 18, hvori den koncentrerede population af fedtvævsafledte celler endvidere omfatter fedtafledte progenitor-celler.
- 20. Anvendelse af en sammensætning ifølge krav 18 eller krav 19, hvori sammensætningen endvidere omfatter et additiv.
- 21. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 18, 19 og 20, hvori sammensætningen omfatter et scaffold.
- 22. Anvendelse af en sammensætning ifølge krav 21, hvori scaffoldet er et resorberbart scaffold.
- 23. Anvendelse af en sammensætning ifølge krav 21, hvori cellerne administreres i kombination med væv eller vævsfragmenter, og hvori ekstraktion og koncentration af fedtvævet og placering af cellerne sker i en enkelt operativ procedures kontekst.
- 24. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 18-23, hvori de fedtvævsafledte celler er modificeret ved genoverførsel.
- 25. Anvendelse af en sammensætning til anvendelse ifølge et hvilket som helst af kravene 18-24, hvori den perifere karsygdom er karakteriseret ved en utilstrækkelig blodgennemstrømning, arteriosklerose en traumatisk skade på et blodkar eller en inflammatorisk arteritis.
- 26. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 18-25, hvori den perifere karsygdom stammer fra kulde, stress eller rygning.
- 27. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 18-26, hvori sammensætningen endvidere omfatter en angiogen faktor eller et immunsupprimerende lægemiddel.
- 28. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 18-27, hvori sammensætningen er formuleret til intravenøs, intramuskulær eller subkutan administration.
- 29. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 18-28, hvori behandlingen af perifer karsygdom (PVD) uden for hjertet og centralnervesystemet omfatter reduktion i claudicatio.
- 30. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 18-29, hvori behandlingen af perifer karsygdom (PVD) uden for hjertet og centralnervesystemet omfatter heling af iskæmiske ulcerationer.
- 31. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 18-30, hvori behandlingen af perifer karsygdom (PVD) uden for hjertet og centralnervesystemet omfatter øgning af oxygenkoncentrationen i vævet målt ved kropspletysmografi.
- 32. Anvendelse af en sammensætning ifølge et hvilket som helst af kraven 18-31, hvori behandlingen af perifer karsygdom (PVD) uden for hjertet og centralnervesystemet omfatter forbedring i det ankel-brakiale indeks (ABI).
- 33. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 18-32, hvori sammensætningen er formuleret til flerdosisadministration.
- 34. Anvendelse af en sammensætning til anvendelse ifølge krav 20, hvori additivet omfatter andre celler, væv eller vævsfragmenter.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50358903P | 2003-09-17 | 2003-09-17 | |
PCT/US2004/021480 WO2005034843A2 (en) | 2003-09-17 | 2004-07-01 | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1670315T3 true DK1670315T3 (da) | 2017-08-07 |
Family
ID=34434859
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04756641.9T DK1670315T3 (da) | 2003-09-17 | 2004-07-01 | Fremgangsmåder til anvendelse af fedtafledte regenerative celler i behandlingen af perifer karsygdom |
DK10183850.6T DK2348103T3 (da) | 2003-09-17 | 2004-07-01 | Fremgangsmåder til anvendelse af regenerative celler til behandling af perifer karsygdom og beslægtede sygdomme |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10183850.6T DK2348103T3 (da) | 2003-09-17 | 2004-07-01 | Fremgangsmåder til anvendelse af regenerative celler til behandling af perifer karsygdom og beslægtede sygdomme |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP1670315B1 (da) |
JP (1) | JP5019511B2 (da) |
CN (1) | CN1878470A (da) |
AU (1) | AU2004280149A1 (da) |
BR (1) | BRPI0414455A (da) |
CA (1) | CA2539346A1 (da) |
DK (2) | DK1670315T3 (da) |
ES (1) | ES2633604T3 (da) |
MX (1) | MXPA06003088A (da) |
SG (1) | SG146666A1 (da) |
WO (1) | WO2005034843A2 (da) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10589268B2 (en) | 2016-06-08 | 2020-03-17 | The Regents Of The University Of California | Method and device for processing tissues and cells |
US10683480B2 (en) | 2013-06-21 | 2020-06-16 | The Regents Of The University Of California | Microfluidic tumor tissue dissociation device and method |
US10722540B1 (en) | 2016-02-01 | 2020-07-28 | The Regents Of The University Of California | Microfluidic device and method for shear stress-induced transformation of cells |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR298901A0 (en) | 2001-02-07 | 2001-03-08 | McComb Foundation, Inc., The | Cell suspension preparation technique and device |
US9597395B2 (en) | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
US20050048035A1 (en) | 2001-12-07 | 2005-03-03 | Fraser John K. | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders |
US20050095228A1 (en) | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
EP1572071B1 (en) | 2001-12-07 | 2018-10-03 | Cytori Therapeutics, Inc. | Methods for preparing fresh adipose tissue-derived cells and uses in treating patients |
US7771716B2 (en) | 2001-12-07 | 2010-08-10 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
US7585670B2 (en) | 2001-12-07 | 2009-09-08 | Cytori Therapeutics, Inc. | Automated methods for isolating and using clinically safe adipose derived regenerative cells |
US20030205538A1 (en) | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
US7992725B2 (en) | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
AU2003249642A1 (en) | 2002-05-24 | 2003-12-12 | Biomet Manufacturing Corp. | Apparatus and method for separating and concentrating fluids containing multiple components |
US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
WO2006014156A1 (en) * | 2004-07-02 | 2006-02-09 | Macropore Biosurgery, Inc. | Systems and methods for isolating and using clinically safe adipose derived regenerative cells |
US7708152B2 (en) | 2005-02-07 | 2010-05-04 | Hanuman Llc | Method and apparatus for preparing platelet rich plasma and concentrates thereof |
US7866485B2 (en) | 2005-02-07 | 2011-01-11 | Hanuman, Llc | Apparatus and method for preparing platelet rich plasma and concentrates thereof |
EP1848472B1 (en) * | 2005-02-07 | 2015-04-01 | Hanuman LLC | Platelet rich plasma concentrate apparatus and method |
US9581942B1 (en) | 2005-03-23 | 2017-02-28 | Shippert Enterprises, Llc | Tissue transfer method and apparatus |
US7794449B2 (en) | 2005-03-23 | 2010-09-14 | Shippert Ronald D | Tissue transplantation method and apparatus |
US8062286B2 (en) | 2005-03-23 | 2011-11-22 | Shippert Ronald D | Tissue transplantation method and apparatus |
US7789872B2 (en) | 2005-03-23 | 2010-09-07 | Shippert Ronald D | Tissue transplantation method and apparatus |
US7780649B2 (en) | 2005-03-23 | 2010-08-24 | Shippert Ronald D | Tissue transplantation method and apparatus |
US8622997B2 (en) | 2005-03-23 | 2014-01-07 | Ronald D. Shippert | Tissue transfer method and apparatus |
PL1885382T3 (pl) * | 2005-05-25 | 2011-09-30 | Cytori Therapeutics Inc | Sposoby stosowania komórek pochodzących z tkanki tłuszczowej w leczeniu stanów układu sercowo-naczyniowego |
AU2013216683B2 (en) * | 2005-05-25 | 2016-06-23 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
US7806276B2 (en) * | 2007-04-12 | 2010-10-05 | Hanuman, Llc | Buoy suspension fractionation system |
KR20080103637A (ko) * | 2007-05-25 | 2008-11-28 | 주식회사 알앤엘바이오 | 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물 |
JP5196890B2 (ja) * | 2007-06-29 | 2013-05-15 | オリンパス株式会社 | 有核細胞回収装置および有核細胞の回収方法 |
KR20140107677A (ko) | 2007-09-19 | 2014-09-04 | 플루리스템 리미티드 | 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도 |
WO2009108890A1 (en) | 2008-02-27 | 2009-09-03 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
WO2009111338A1 (en) | 2008-02-29 | 2009-09-11 | Biomet Manufacturing Corp. | A system and process for separating a material |
US8012077B2 (en) | 2008-05-23 | 2011-09-06 | Biomet Biologics, Llc | Blood separating device |
WO2010021993A1 (en) | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
US8187475B2 (en) | 2009-03-06 | 2012-05-29 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
CA2760574C (en) | 2009-05-01 | 2020-10-27 | Cytori Therapeutics, Inc. | Device and method for preparing tissue for an adipose graft |
JP5431786B2 (ja) * | 2009-05-12 | 2014-03-05 | 國立中央大學 | 造血幹細胞を単離、生体外(exvivo)増殖および回収するためのシステムおよび方法 |
US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
US8887770B1 (en) | 2011-03-17 | 2014-11-18 | Ronald D. Shippert | Vessel fill control method and apparatus |
JP5628131B2 (ja) * | 2011-10-19 | 2014-11-19 | サイトリ セラピューティクス インコーポレイテッド | 心血管状態の治療において脂肪組織由来細胞を使用する方法 |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US9468709B2 (en) | 2012-11-12 | 2016-10-18 | Shippert Enterprises, Llc | Syringe fill method and apparatus |
AU2013205148B2 (en) | 2013-03-14 | 2014-10-30 | AVITA Medical Americas, LLC | Systems and methods for tissue processing and preparation of cell suspension therefrom |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
WO2015149098A1 (de) | 2014-03-31 | 2015-10-08 | Liporegena Gmbh | Vorrichtung zur entnahme und portionierung von fettgewebe |
US10772997B2 (en) | 2014-05-15 | 2020-09-15 | Ronald D. Shippert | Tissue parcelization method and apparatus |
US9713810B2 (en) | 2015-03-30 | 2017-07-25 | Biomet Biologics, Llc | Cell washing plunger using centrifugal force |
US9757721B2 (en) | 2015-05-11 | 2017-09-12 | Biomet Biologics, Llc | Cell washing plunger using centrifugal force |
MX2018001511A (es) | 2015-08-04 | 2018-08-01 | Univ Duke | Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos. |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
WO2017141831A1 (ja) * | 2016-02-16 | 2017-08-24 | ロート製薬株式会社 | 脂肪組織由来間質細胞を含む虚血性疾患治療剤およびその製造方法 |
WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
US11554097B2 (en) | 2017-05-15 | 2023-01-17 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
US11680083B2 (en) | 2017-06-30 | 2023-06-20 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
JP7282679B2 (ja) * | 2017-09-15 | 2023-05-29 | 株式会社カネカ | 細胞含有試料からの細胞の遊離方法 |
WO2020028806A1 (en) | 2018-08-02 | 2020-02-06 | Duke University | Dual agonist fusion proteins |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
AU2021283961A1 (en) * | 2020-06-05 | 2023-01-19 | Duke University | Compositions and methods for augmenting autologous fat grafts |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5470307A (en) * | 1994-03-16 | 1995-11-28 | Lindall; Arnold W. | Catheter system for controllably releasing a therapeutic agent at a remote tissue site |
US6238908B1 (en) | 1995-06-07 | 2001-05-29 | Aastrom Biosciences, Inc. | Apparatus and method for maintaining and growth biological cells |
FR2742662B1 (fr) | 1995-12-21 | 1998-01-23 | Centre Nat Rech Scient | Anticorps anti-idiotypiques du facteur de croissance endotheliale vasculaire et leur utilisation comme medicaments |
US5919234A (en) | 1996-08-19 | 1999-07-06 | Macropore, Inc. | Resorbable, macro-porous, non-collapsing and flexible membrane barrier for skeletal repair and regeneration |
US6280473B1 (en) | 1996-08-19 | 2001-08-28 | Macropore, Inc. | Resorbable, macro-porous, non-collapsing and flexible membrane barrier for skeletal repair and regeneration |
US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
US6269716B1 (en) | 1998-11-18 | 2001-08-07 | Macropore, Inc. | High-torque resorbable screws |
JP2002510530A (ja) | 1998-04-07 | 2002-04-09 | マクロポア インコーポレイテッド | 組織案内表面波形部付きのメンブレン |
US6001642A (en) | 1998-06-29 | 1999-12-14 | Wyle Laboratories, Inc. Life Sciences | Bioreactor and cell culturing processes using the bioreactor |
KR100968164B1 (ko) * | 1999-03-10 | 2010-07-06 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 지방 유래 간세포 및 격자 |
WO2001036663A2 (en) | 1999-11-15 | 2001-05-25 | Chemclean Corporation | Bio-burden visualization system |
DK1265550T3 (da) | 2000-03-10 | 2005-07-25 | Macropore Biosurgery Inc | Resorberbar mikromembran til formindskelse af arvæv |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
US6635064B2 (en) | 2000-10-04 | 2003-10-21 | Macropore Biosurgery, Inc. | Non-scatterable, radio-opaque material for medical imaging applications |
EP1381410A2 (en) * | 2001-04-09 | 2004-01-21 | Medtronic, Inc. | Methods of isolating blood components using a centrifuge and uses thereof |
US20030054331A1 (en) * | 2001-09-14 | 2003-03-20 | Stemsource, Inc. | Preservation of non embryonic cells from non hematopoietic tissues |
EP1572071B1 (en) * | 2001-12-07 | 2018-10-03 | Cytori Therapeutics, Inc. | Methods for preparing fresh adipose tissue-derived cells and uses in treating patients |
WO2003080801A2 (en) * | 2002-03-19 | 2003-10-02 | Advanced Research & Technology Transfer | Adipose stromal stem cells for tissue and vascular modification |
WO2004013275A2 (fr) * | 2002-07-31 | 2004-02-12 | Yves Saint-Laurent Parfums | Cellules souches issues de tissu adipeux et cellules differenciees issues de ces cellules |
ES2373551T3 (es) * | 2003-02-20 | 2012-02-06 | Cytori Therapeutics, Inc. | Métodos para usar células derivadas de tejido adiposo en el tratamiento de afecciones cardiovasculares. |
-
2004
- 2004-07-01 CN CNA2004800333682A patent/CN1878470A/zh active Pending
- 2004-07-01 CA CA002539346A patent/CA2539346A1/en not_active Abandoned
- 2004-07-01 JP JP2006526870A patent/JP5019511B2/ja active Active
- 2004-07-01 AU AU2004280149A patent/AU2004280149A1/en not_active Abandoned
- 2004-07-01 MX MXPA06003088A patent/MXPA06003088A/es not_active Application Discontinuation
- 2004-07-01 BR BRPI0414455-4A patent/BRPI0414455A/pt not_active IP Right Cessation
- 2004-07-01 ES ES04756641.9T patent/ES2633604T3/es active Active
- 2004-07-01 SG SG200806960-1A patent/SG146666A1/en unknown
- 2004-07-01 EP EP04756641.9A patent/EP1670315B1/en not_active Not-in-force
- 2004-07-01 DK DK04756641.9T patent/DK1670315T3/da active
- 2004-07-01 EP EP10183850.6A patent/EP2348103B1/en not_active Not-in-force
- 2004-07-01 DK DK10183850.6T patent/DK2348103T3/da active
- 2004-07-01 WO PCT/US2004/021480 patent/WO2005034843A2/en active Application Filing
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10683480B2 (en) | 2013-06-21 | 2020-06-16 | The Regents Of The University Of California | Microfluidic tumor tissue dissociation device and method |
US11427798B2 (en) | 2013-06-21 | 2022-08-30 | The Regents Of The University Of California | Microfluidic tissue dissociation device and method |
US10722540B1 (en) | 2016-02-01 | 2020-07-28 | The Regents Of The University Of California | Microfluidic device and method for shear stress-induced transformation of cells |
US10589268B2 (en) | 2016-06-08 | 2020-03-17 | The Regents Of The University Of California | Method and device for processing tissues and cells |
US11130127B2 (en) | 2016-06-08 | 2021-09-28 | The Regents Of The University Of California | Method and device for processing tissues and cells |
Also Published As
Publication number | Publication date |
---|---|
AU2004280149A1 (en) | 2005-04-21 |
WO2005034843A2 (en) | 2005-04-21 |
EP1670315B1 (en) | 2017-04-19 |
SG146666A1 (en) | 2008-10-30 |
EP2348103A2 (en) | 2011-07-27 |
CA2539346A1 (en) | 2005-04-21 |
EP1670315A2 (en) | 2006-06-21 |
ES2633604T3 (es) | 2017-09-22 |
CN1878470A (zh) | 2006-12-13 |
JP2007505904A (ja) | 2007-03-15 |
EP1670315A4 (en) | 2006-11-15 |
MXPA06003088A (es) | 2006-06-20 |
BRPI0414455A (pt) | 2006-11-14 |
WO2005034843A3 (en) | 2005-06-09 |
JP5019511B2 (ja) | 2012-09-05 |
DK2348103T3 (da) | 2019-09-30 |
EP2348103B1 (en) | 2019-06-19 |
EP2348103A3 (en) | 2012-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9849149B2 (en) | Methods of using regenerative cells in the treatment of erectile dysfunction | |
US9872877B2 (en) | Methods of using regenerative cells to promote epithelialization or neodermis formation | |
DK1670315T3 (da) | Fremgangsmåder til anvendelse af fedtafledte regenerative celler i behandlingen af perifer karsygdom | |
US9504718B2 (en) | Methods of using adipose derived regenerative cells in the treatment of renal diseases and disorders | |
EP1778833B1 (en) | Methods of using regenerative cells to promote wound healing | |
EP1776126B1 (en) | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders | |
EP1778834B1 (en) | Methods of using regenerative cells in the treatment of renal diseases and disorders |